Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Urologe A ; 58(7): 809-820, 2019 Jul.
Article in German | MEDLINE | ID: mdl-31263939

ABSTRACT

Both the demographic shift and progress in medicine are resulting in an increasingly longer life expectancy. It is presumed that a mean age of 90 years will be achieved within the next decade in many countries. Thus, geriatric medicine, which is committed to the specific needs of older, often frail and frequently comorbid patients, is becoming increasingly more important. The prevalence of infections of the genitourinary tract increases with age, simultaneously, a critical and conscious use of antibiotics is required in terms of antimicrobial treatment. The intention of the present review is to make the reader aware of the specific characteristics of urinary tract infections and asymptomatic bacteriuria in the older patient population in terms of epidemiology, spectrum of pathogens and resistance as well as the indications for and performance of antimicrobial treatment.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Urinary Tract Infections/drug therapy , Aged , Aged, 80 and over , Antibiotic Prophylaxis/methods , Bacteriuria/drug therapy , Humans , Treatment Outcome
3.
Urologe A ; 58(4): 437-450, 2019 Apr.
Article in German | MEDLINE | ID: mdl-30923856

ABSTRACT

The spectrum of surgical procedures for the minimally invasive treatment of benign prostatic hyperplasia (BPH) has significantly increased over the last two decades. The simple suprapubic prostatectomy (subtotal prostatectomy, SP) has largely lost relevance in current practice. On the other hand, transurethral resection of the prostate (TURP) has been further standardized and potentially made safer by the introduction of the bipolar technique and low-pressure systems.Transurethral (endoscopic) enucleation techniques (endoscopic enucleation of the prostate, EEP) are increasingly competing with the current gold standard TURP and are replacing SP for treatment of larger adenomas. This approach is especially related to the rapid development of laser technology, which has sustainably changed the face of modern BPH treatment in a similar way to stone therapy. This has been incorporated in the clinical patient management, clinical studies and standardization of numerous surgical techniques that are systematically described in this article. Additionally, efforts have also been made to use other energy sources, such as bipolar current in EEP. With respect to scientific objectivity, high-quality clinical trials are regularly published which further strengthen the position of EEP.


Subject(s)
Laser Therapy , Prostatic Hyperplasia , Transurethral Resection of Prostate , Endoscopy , Humans , Male , Prostatectomy , Prostatic Hyperplasia/therapy
4.
Urologe A ; 56(9): 1193-1206, 2017 Sep.
Article in German | MEDLINE | ID: mdl-28762032

ABSTRACT

Correct positioning of patients during preoperative preparations is essential for success of the intervention to avoid any positioning trauma and to provide the best access to the targeted structures. The appropriate positioning (and optimal performance) means that complications are avoided and also makes an essential contribution to the smooth course of the surgical intervention. A correct position is essential particularly in urology because the organs assigned to the discipline of urology are anatomically mostly difficult to reach. A further important function of the correct positioning technique is the avoidance of injuries to the patient. This article summarizes the most common positioning techniques in urological interventions with special emphasis on the explanation of practical advice, helpful tips and possible complications that can enable even junior surgeons to correctly perform the appropriate positioning technique.


Subject(s)
Patient Positioning/methods , Urologic Diseases/surgery , Urologic Surgical Procedures/methods , Equipment Design , Female , Humans , Intraoperative Complications/prevention & control , Male , Operating Tables , Patient Positioning/instrumentation , Postoperative Complications/prevention & control , Preoperative Care/methods
6.
Urologe A ; 54(4): 484-90, 2015 Apr.
Article in German | MEDLINE | ID: mdl-25784271

ABSTRACT

Nonmuscle-invasive bladder cancer (NMIBC) comprises a very heterogeneous group of malignancies; the biological behavior of these tumors depends primarily on their grading. Low-grade NMIBC are characterized by a high propensity for recurrence but a very low risk for progression to muscle invasion or metastatic disease. Thus, the first line goal of diagnostic procedures and therapy is reliable visualization and complete resection of all foci. Cytology and other urine-based markers fail due to insufficient sensitivity. A second resection might be necessary only in selected intermediate risk cases; the positive effect of maintenance instillation protocols beyond a single postoperative instillation is questionable for the majority of patients. Risk stratification, e.g., according to the EORTC or EAU proposals, also makes sense in low grade NMIBC.


Subject(s)
Biomarkers, Tumor/urine , Carcinoma, Transitional Cell/pathology , Carcinoma, Transitional Cell/therapy , Cystoscopy/methods , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/therapy , Carcinoma, Transitional Cell/urine , Humans , Muscle Neoplasms/pathology , Muscle Neoplasms/therapy , Muscle Neoplasms/urine , Neoplasm Grading , Surgery, Computer-Assisted/methods , Urinary Bladder Neoplasms/urine
7.
Urologe A ; 54(6): 804-10, 2015 Jun.
Article in German | MEDLINE | ID: mdl-25503720

ABSTRACT

BACKGROUND: The indications for nephron-sparing surgery have been considerably extended by guideline recommendations in recent years. It remains unclear whether clinical practice still reflects these new guidelines. OBJECTIVE: In this retrospective, monocentric analysis at a tertiary referral center the indications for partial nephrectomy over a 13-year period were evaluated. METHODS: In a retrospective database analysis all cases of surgically treated renal masses from 2001 to 2013 were evaluated. Besides demographic, tumor-specific and perioperative variables the development of the surgical technique depending on the tumor stage was evaluated. RESULTS AND DISCUSSION: The proportion of nephron-sparing surgery cases increased from below 20 % in 2001 to 35 % in 2013 in the entire cohort. For stage T1a tumors, partial nephrectomy increased from approximately 50 % to over 90 % and for T1b tumors it rose from 10 % to 50 %. Logistic regression revealed stage 1 tumors to be predictive of partial nephrectomy over the complete evaluation period. Extending the indications for partial nephrectomy even to higher stages is under discussion but not yet supported by data from prospective, controlled studies.


Subject(s)
Guideline Adherence/statistics & numerical data , Kidney Neoplasms/epidemiology , Kidney Neoplasms/surgery , Nephrectomy/standards , Nephrons/surgery , Organ Sparing Treatments/statistics & numerical data , Adult , Aged , Aged, 80 and over , Female , Germany/epidemiology , Guideline Adherence/standards , Humans , Longitudinal Studies , Male , Middle Aged , Nephrectomy/statistics & numerical data , Organ Sparing Treatments/standards , Organ Sparing Treatments/trends , Patient Selection , Practice Guidelines as Topic , Practice Patterns, Physicians'/statistics & numerical data , Practice Patterns, Physicians'/trends , Prevalence , Retrospective Studies , Risk Factors , Treatment Outcome
8.
Urologe A ; 51(6): 843-7, 2012 Jun.
Article in German | MEDLINE | ID: mdl-22476740

ABSTRACT

Overdiagnosis and resulting overtreatment in prostate cancer are under intensive discussion both in the urologic communities and in the public media. Sensitive and specific diagnostic modalities could be one step forward to overcome this problem. Choline PET/CT provides fusion imaging that combines anatomical/morphological information with metabolic/functional data. Despite promising preclinical data and interesting initial clinical results, this cost-intensive and logistically demanding technology has not yet found its way into routine clinical practice; the German and European guideline recommendations are careful and reluctant. This review has the goal to give an overview of the recent data both on initial diagnosis and on staging/diagnosis for biochemical recurrence by choline PET/CT and to summarize the possible role of this innovative technology in the future, if adequate research projects can be realized.


Subject(s)
Choline , Evidence-Based Medicine , Multimodal Imaging/methods , Neoplasm Recurrence, Local/diagnosis , Positron-Emission Tomography , Prostatic Neoplasms/diagnosis , Tomography, X-Ray Computed , Clinical Trials as Topic , Humans , Male , Prognosis , Radiopharmaceuticals , Reproducibility of Results , Sensitivity and Specificity
9.
Urologe A ; 50(2): 221-6, 2011 Feb.
Article in German | MEDLINE | ID: mdl-21246347

ABSTRACT

One of the principal objects of the scientific research network "German Bladder Cancer Network" is to consolidate research activities on bladder cancer. An overview about directions of current projects on this research topic was given at the annual meeting of the German Association of Urology in Düsseldorf from September 22 to 25 September 2010. As representatives of the"German Bladder Cancer Network" we summarize and comment on some of the most interesting projects on bladder cancer presented at this meeting. A special focus will be on current developments in the field of uropathology and on different aspects in preclinical research on bladder cancer.


Subject(s)
Evidence-Based Medicine , Medical Oncology/trends , Urinary Bladder Neoplasms/diagnosis , Urinary Bladder Neoplasms/therapy , Urology/trends , Germany , Humans
10.
Urologe A ; 49(8): 952-6, 2010 Aug.
Article in German | MEDLINE | ID: mdl-20182691

ABSTRACT

This report describes the case of a 65-year-old patient who underwent radical prostatectomy in our department. Intraoperatively we detected suspicious lymph nodes on the left side. The histopathological examination revealed histiocytosis and foreign body giant cells but no sign of tumor. The enlarged lymph nodes were ascribed to an ipsilateral total hip arthroplasty performed 14 years previously because of progressive coxarthrosis. Lymphadenitis after total hip arthroplasty is frequently observed. Histopathologically and with the use of polarized light microscopy, histiocytosis and wear particles such as titanium, polyethylene, and polyethylene-methylacrylate may be detected. When operating on patients with arthroplasty of a lower limb, particularly those with a total endoprosthesis, the surgeon should bear in mind that changes in lymph node consistency and size do not necessarily indicate tumor involvement or metastases.


Subject(s)
Arthroplasty, Replacement, Hip/adverse effects , Lymphadenitis/diagnosis , Lymphadenitis/etiology , Prosthesis-Related Infections/diagnosis , Prosthesis-Related Infections/etiology , Adenocarcinoma/diagnosis , Adenocarcinoma/secondary , Aged , Diagnosis, Differential , Humans , Lymphatic Metastasis , Male , Pelvis , Prostatic Neoplasms/diagnosis
11.
Aktuelle Urol ; 40(3): 164-8, 2009 May.
Article in German | MEDLINE | ID: mdl-19370533

ABSTRACT

BACKGROUND: Until today, docetaxel is the only EMEA and FDA approved active agent in hormone refractory prostate cancer (HRPC). In the absence of other effective and approved drugs we evaluated the toxicity and efficacy of intermittent-docetaxel-chemotherapy in patients whose cancers progressed after successful first-line docetaxel therapy. METHODS: 46, 18, and 5 patients with HRPC received 1, 2, or 3 cycles of docetaxel based chemotherapy. Toxicity, PSA response and general condition were evaluated systematically. SPSS 15.0 was applied for statistic analysis. RESULTS: 26 (56 %) patients achieved a PSA response of > 50 %, another 10 (22 %) patients of up to 50 %; 10 (22 %) patients were progressive under docetaxel. The median overall survival of the whole cohort calculated from the first docetaxel application was 16 (3-60 +) months. Tolerance, toxicity and general condition were crucial for the administration of a second cycle (n = 18); in contrast, age or the degree of the PSA decline in cycle 1 did not seem to be of importance. The -median overall survival of all patients who -received at least two blocks was 35 months; more-over, 13 / 18 patients achieved a biochemical response in cycle 2. Toxicity did not rise significantly. Five patients were given a third docetaxel cycle, three of whom responded. Higher frequencies of -grade 3 / 4 stomatitis, skin toxicity and leukocytopaenia were observed. CONCLUSION: Intermittent docetaxel therapy is well tolerated and shows high response rates in the sec-ond and third sequences of treatment in select-ed HRPC patients who presented with low docetaxel toxicity, good clinical condition and responded to prior docetaxel-based treatment.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/toxicity , Bone Neoplasms/drug therapy , Bone Neoplasms/secondary , Prostatic Neoplasms/drug therapy , Taxoids/toxicity , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/blood , Bone Neoplasms/blood , Bone Neoplasms/pathology , Disease Progression , Docetaxel , Dose-Response Relationship, Drug , Drug Administration Schedule , Estramustine/administration & dosage , Estramustine/toxicity , Humans , Male , Middle Aged , Mitoxantrone/administration & dosage , Mitoxantrone/toxicity , Neoplasm Staging , Palliative Care , Prostate-Specific Antigen/blood , Prostatic Neoplasms/blood , Prostatic Neoplasms/mortality , Prostatic Neoplasms/pathology , Retreatment , Survival Rate , Taxoids/administration & dosage
12.
Urologe A ; 48(2): 137-42, 2009 Feb.
Article in German | MEDLINE | ID: mdl-19142627

ABSTRACT

Fast-track (FT) protocols in visceral surgery incorporate innovative aspects of analgesia, bowel preparation, enteralization, and drainage management. In elective colorectal surgery, these concepts are the standard of care. In uro-oncological surgery, however, they are used very reluctantly, although the available data show that early nasogastric tube removal and enteralization and the omission of preoperative bowel preparation have positive effects on convalescence and hospital stay. The work presented here was initiated to compare traditional and FT management in a randomized fashion, focusing on complication rates and the course of enteralization as outcome measures. Complication rates, especially of bowel-associated complications, were not increased in the FT group. The postoperative stay on the intermediate care unit was significantly shorter in the FT cohort, and enteralization was completed significantly earlier. FT management is not associated with an increased risk of major complications in urinary diversion surgery. Controlled clinical trials are needed to further evaluate important aspects of a standardized perioperative plan of care (including antibiotic regimen and earlier removal of ureteral and neobladder catheters).


Subject(s)
Cystectomy/methods , Evidence-Based Medicine , Perioperative Care/methods , Urinary Bladder/surgery , Urinary Diversion/methods , Humans
13.
J Cancer Res Clin Oncol ; 135(6): 799-805, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19023595

ABSTRACT

OBJECTIVES: Papillary renal cell carcinoma (pRCC) represents the largest subgroup of non-clear-cell kidney cancer. In this study, we assessed tumour characteristics and long-term prognosis of patients with pRCC in comparison with conventional clear-cell cancer (ccRCC). METHODS: We evaluated 744 patients who had undergone renal surgery for RCC between 1990 and 2005. The mean follow-up was 5.6 years, the patients being followed-up until December 2007. RESULTS: Both groups, pRCC and ccRCC, were alike concerning age, body mass index, and the incidence of regional lymph node or distant metastasis at diagnosis. The percentage of male patients was higher in pRCC than in ccRCC (73.8 vs. 60.3%, p = 0.006). Even though patients with pRCC presented more often with smaller (p = 0.039) and low-grade tumours (p = 0.006), there was no statistically significant difference in tumour recurrence or tumour related death. Kaplan-Meier curves revealed no differences regarding tumour specific survival between pRCC and ccRCC (p = 0.94; 5-year survival 78 vs. 77%). CONCLUSIONS: Even though pRCC and ccRCC differ significantly in many aspects including histology and genetic alterations, their long term prognosis is comparable. As we could not confirm a favourable clinical course for pRCC in general, standardised aftercare programmes and-if necessary-systemic treatment, especially in the era of novel targeted drugs, are also needed for this common RCC subtype.


Subject(s)
Carcinoma, Renal Cell/pathology , Kidney Neoplasms/pathology , Adenocarcinoma, Clear Cell/pathology , Adult , Aged , Aged, 80 and over , Carcinoma, Papillary/pathology , Female , Follow-Up Studies , Germany/epidemiology , Humans , Incidence , Kaplan-Meier Estimate , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Staging , Prognosis , Retrospective Studies , Time Factors
14.
Urologe A ; 47(9): 1182, 1184-6, 2008 Sep.
Article in German | MEDLINE | ID: mdl-18679648

ABSTRACT

BACKGROUND: Renal cell carcinoma (RCC) occurs twice as often in men as in women; however, the influence of gender on stage, grade, subtype and prognosis has not been studied in detail. METHODS: This study included 780 patients treated by (partial) nephrectomy at our institution in Marburg between 1990 and 2005. The mean follow-up was 5.44 years. RESULTS: Of the 780 patients, 486 (62%) were men and 294 (38%) were women. Women were significantly older (mean, 65.3 vs. 62.2 years; p<0.001, t-test), presented at lower T stages (p=0.046, chi(2)) and suffered metastasis less frequently at diagnosis (p=0.026, chi(2)). In addition, women more frequently had clear cell tumours (85.2% vs. 78.3%) and less frequently papillary tumours (11.0% vs. 18.8%) than men (p=0.026, chi(2)). In contrast, men had an increased risk of death from RCC (HR 1.23, CI 0.92-1.63); Kaplan-Meier curves revealed a significant difference in tumour-specific survival between men and women (p=0.033, log rank; 5-year survival 74% vs. 83%). However, unlike tumour stage and tumour grade, gender could not be retained as a significant independent prognostic marker in multivariate analysis. CONCLUSION: In general, RCC in men is characterized by higher tumour stages and more frequent metastasis at diagnosis along with inferior tumour-specific survival. However, as gender failed to qualify as an independent prognostic marker for tumour-specific survival, delayed diagnosis due to insufficient routine medical check-up and/or a more aggressive tumour biology might be be a concurrent cause. Thorough regular medical check-ups for men, also with regard to RCC, are thus mandatory.


Subject(s)
Carcinoma, Renal Cell/mortality , Kidney Neoplasms/mortality , Adult , Age Factors , Aged , Aged, 80 and over , Carcinoma, Renal Cell/pathology , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Kidney Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Proportional Hazards Models , Sex Factors
15.
Urologe A ; 47(9): 1133-4, 1136, 2008 Sep.
Article in German | MEDLINE | ID: mdl-18679650

ABSTRACT

CpG-oligodeoxynucleotides (CpG-ODN) are potent stimulators of the innate immune system. They promote a Th1-biased immune response with antineoplastic potential. We recently demonstrated antitumoral effects of CpG-ODN in murine transitional cell carcinoma (TCC) models. The purpose of the present work was to more precisely define the immunological nature of this immunotherapeutic approach to TCC.MB-49 TCC was established in female C57/Bl6 mice by intravesical tumor cell instillation after poly-L-lysine conditioning of the bladder (day 0) as described previously. Three groups of six mice were treated: intravesical instillation of 50 microl PBS on days 1, 3, 5, and 7 (group 1, untreated control); 10 nmol CpG 1668 on days 1, 3, 5, and 7 (group 2); and 10 nmol GpC 1668 on days 1, 3, 5, and 7 (group 3). Six native bladders served as no-treatment/no-tumor controls (group 4). Mice were sacrificed on day 11; bladders and draining lymph nodes were removed, and mRNA was prepared for quantitative real-time polymerase chain reaction. Samples were analyzed on a Bio-Rad iCycler for IL 10, TGF-beta, IL 12, and IFNgamma expression; threshold values were compared to beta-actin as housekeeping gene.Tumor take was 100%. Three animals in group 1 had to be sacrificed in advance due to rapid tumor progression. Relative cytokine expression was comparable in groups 1 and 4. IL-10, IL-12, TGF-beta, and IFNgamma were overexpressed in groups 2 and 3. CpG-ODN treatment of murine TCC results in overexpression of both classic Th1 cytokines (IL 12 and IFNgamma) and the Th2 marker IL 10. TGF-beta expression is increased as well. These phenomena are not induced by the growing TCC but by CpG-ODN therapy. They are accompanied by an objective clinical response, as we were able to show recently. Immunostimulatory DNA holds promise to be a novel therapeutic agent in TCC.


Subject(s)
Adjuvants, Immunologic/pharmacology , Carcinoma, Transitional Cell/immunology , Disease Models, Animal , Oligodeoxyribonucleotides/pharmacology , Urinary Bladder Neoplasms/immunology , Administration, Intravesical , Animals , Cell Line, Tumor , Cytokines/metabolism , Female , Humans , Mice , Mice, Inbred C57BL , Neoplasm Transplantation/immunology
16.
Urologe A ; 47(9): 1137-40, 2008 Sep.
Article in German | MEDLINE | ID: mdl-18651122

ABSTRACT

Up to now markers for transitional cell carcinoma of the bladder (TCC) are missing. Fibronectin (FN) seems to play a key role in progression and invasion of malignant tumors. The aim of this study was to assess the value of cellular FN (cFN), a more specific subform of produced FN, in different stages of TCC.cFN was determined using a highly sensitive immunoassay which we developed. Blood samples were taken of 45 patients with the first diagnosis of TCC before undergoing TUR-B and 6 patients with metastatic TCC before chemotherapy; 70 patients with nonmalignant urological disorders served as a control group.Patients with TCC showed significantly elevated cFN plasma levels compared to controls (p<0.05). Patients with muscle-invasive disease (n=15) showed significantly higher cFN plasma levels compared to the group with superficial TCC. Patients with metastatic TCC showed the highest, but not significantly elevated cFN plasma levels compared to patients with muscle-invasive TCC.The elevated cFN plasma levels in TCC underline the important role of cFN for tumor progression and its potential role as a marker for TCC. Upcoming investigations are necessary to prove the value of the potential marker cFN during follow-up and its impact as a prognostic factor for recurrence and progression of TCC.


Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Transitional Cell/pathology , Fibronectins/blood , Urinary Bladder Neoplasms/pathology , Aged , Carcinoma, Transitional Cell/surgery , Cystoscopy , Female , Humans , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Predictive Value of Tests , Urinary Bladder/pathology , Urinary Bladder Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...